News & Updates

Combination treatment with pioglitazone plus a sodium-glucose co-transporter 2 (SGLT2) inhibitor helps reduce the risk of developing major adverse cardiovascular events (MACE) and heart failure in individuals with type 2 diabetes mellitus (T2DM) who have no history of cardiovascular disease (CV), as reported in a study.

Not enough children in Singapore are getting vaccinated against influenza, whereas the number of those who are receiving pneumococcal shots has steadily increased over time.

Treatment with pazopanib combined with chemotherapy leads to better overall response rate (ORR) in patients with recurrent or persistent ovarian cancer but falls short of improving survival, reveals a study. In addition, the combination therapy contributes to an increase in several adverse events (AEs).

First-line treatment with cemiplimab, either as monotherapy or in combination with platinum-based chemotherapy, provides clinical benefits to patients with unresectable locally advanced nonsmall cell lung cancer (NSCLC) who are not candidates for definitive concurrent chemoradiation, as shown by long-term follow-up data from EMPOWER-Lung studies.

Use of psychedelic drugs appears to have some benefits in reducing anxiety and depressive symptoms among patients with cancer or other life-threatening diseases, reports a study.